Prognosis
Astra Data, NovaVax Delay Spur Moderna Vaccine Demand: CEO
- Governments worldwide now approaching Moderna for more supply
- Astra data left buyers confused, disappointed, Bancel says
This article is for subscribers only.
Confusion about AstraZeneca Plc’s Covid-19 vaccine data and delays in Novavax Inc.’s clinical trials are boosting demand worldwide for Moderna Inc.’s shot, according to that company’s chief executive officer.
Stephane Bancel, speaking in a virtual Piper Sandler event on Wednesday, said governments around the world had approached Moderna seeking more supply of its vaccine in the wake of “confusion” and “disappointment” around clinical trial data reported by AstraZeneca and its development partner, the University of Oxford.